Dec 16 (Reuters) - Anesiva Inc:
* Phase 3 trial of Adlea meets primary endpoint to significantly reduce pain
after total knee replacement surgery
* Says trial also met secondary endpoint with Adlea demonstrating a highly
significant reduction in opioid medication consumption
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Phase 3 trial of Adlea meets primary endpoint to significantly reduce pain
after total knee replacement surgery
* Says trial also met secondary endpoint with Adlea demonstrating a highly
significant reduction in opioid medication consumption
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2008. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2008 AFX News
